Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Analyst Ratings Changes

Several research analysts have recently issued reports on RGEN shares. Stifel Nicolaus upped their price objective on Repligen from $165.00 to $207.00 and gave the company a buy rating in a research note on Thursday, February 22nd. KeyCorp upped their price target on shares of Repligen from $210.00 to $220.00 and gave the company an overweight rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase & Co. cut their price target on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $197.75.

Repligen Trading Up 0.4 %

Shares of NASDAQ:RGEN traded up $0.74 during trading on Friday, reaching $167.05. The stock had a trading volume of 454,984 shares, compared to its average volume of 538,521. The stock has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a P/E/G ratio of 5.44 and a beta of 1.03. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13. The firm’s fifty day moving average is $180.81 and its 200 day moving average is $174.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The business had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 EPS. As a group, equities analysts forecast that Repligen will post 1.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.